Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
Department of Public Health and Paediatrics, University of Torino, 10126 Turin, Italy.
Viruses. 2023 Sep 15;15(9):1934. doi: 10.3390/v15091934.
The relationship between superinfection by multidrug-resistant Gram-negative bacteria and mortality among SARS-CoV-2 hospitalized patients is still unclear. Carbapenem-resistant and carbapenemase-producing Enterobacterales are among the most frequently isolated species when it comes to hospital-acquired superinfections among SARS-CoV-2 patients.
Herein, a retrospective study was carried out using data from adult patients hospitalized for COVID-19. The interaction between in-hospital mortality and rectal carriage and superinfection by carbapenemase-producing Enterobacterales and/or carbapenem-resistant was assessed.
The incidence of KPC-producing and/or carbapenem-resistant rectal carriage was 30%. Bloodstream infection and/or pneumonia due to KPC-producing and/or carbapenem-resistant occurred in 20% of patients. A higher Charlson comorbidity index (OR 1.41, 95% CI 1.24-1.59), being submitted to invasive mechanical ventilation/ECMO ≥ 96 h (OR 6.34, 95% CI 3.18-12.62), being treated with systemic corticosteroids (OR 4.67, 95% CI 2.43-9.05) and having lymphopenia at the time of admission (OR 0.54, 95% CI 0.40-0.72) were the features most strongly associated with in-hospital mortality.
Although KPC-producing and/or carbapenem-resistant rectal carriage, and/or bloodstream infection/pneumonia were diagnosed in a remarkable percentage of COVID-19 patients, their impact on in-hospital mortality was not significant. Further studies are needed to assess the burden of antimicrobial resistance as a legacy of COVID-19 in order to identify future prevention opportunities.
耐多药革兰氏阴性菌的超级感染与 COVID-19 住院患者的死亡率之间的关系尚不清楚。当涉及到 COVID-19 患者的医院获得性超级感染时,耐碳青霉烯肠杆菌科细菌和产碳青霉烯酶肠杆菌科细菌是最常分离的物种之一。
本研究使用了 COVID-19 住院患者的数据进行回顾性研究。评估了住院死亡率与产碳青霉烯酶肠杆菌科细菌和/或耐碳青霉烯肠杆菌科细菌直肠携带和超级感染之间的相互作用。
产 KPC 肠杆菌科细菌和/或耐碳青霉烯肠杆菌科细菌直肠携带的发生率为 30%。20%的患者发生了产 KPC 肠杆菌科细菌和/或耐碳青霉烯肠杆菌科细菌的血流感染和/或肺炎。较高的 Charlson 合并症指数(OR 1.41,95%CI 1.24-1.59)、接受有创机械通气/ECMO 治疗≥96 小时(OR 6.34,95%CI 3.18-12.62)、全身皮质类固醇治疗(OR 4.67,95%CI 2.43-9.05)和入院时淋巴细胞减少(OR 0.54,95%CI 0.40-0.72)是与住院死亡率最密切相关的特征。
尽管在相当比例的 COVID-19 患者中诊断出产 KPC 肠杆菌科细菌和/或耐碳青霉烯肠杆菌科细菌直肠携带和/或血流感染/肺炎,但它们对住院死亡率的影响并不显著。需要进一步研究来评估 COVID-19 作为抗生素耐药性负担的遗留问题,以确定未来的预防机会。